Nucleix - Revolutionizing cancer care through earlier detection
@nucleix.com
Pioneering liquid biopsy company revolutionizing cancer care through earlier detection. Our EpiCheck® technology detects cancer methylation patterns in blood and urine, enabling non-invasive screening for bladder and lung cancers.
Nucleix will present data from an abstract describing the implications of applying the company’s Bladder EpiCheck® urine test as an adjunct to routine surveillance by white light cystoscopy in all high-risk non-muscle invasive bladder cancer patients at the AUA's 2025 Annual Meeting in Las Vegas.
Nucleix to Present Data Showcasing Performance and Clinical Utility of Bladder EpiCheck® Monitoring in Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence at AUA 2025
Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, will present data from an abstract describing the implica...
www.businesswire.com
April 26, 2025 at 12:23 AM
Nucleix will present data from an abstract describing the implications of applying the company’s Bladder EpiCheck® urine test as an adjunct to routine surveillance by white light cystoscopy in all high-risk non-muscle invasive bladder cancer patients at the AUA's 2025 Annual Meeting in Las Vegas.